High Intensity Focused Ultrasound (HIFU) Thalamotomy as a Safe and Effective Treatment of Essential Tremor (ET) in Older Populations and those with Comorbidities
- 1Indiana University School of Medicine
Abstract
Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) has been demonstrated to be a safe and effective minimally invasive therapy for essential tremor (ET). However, it is not clear whether older adults ([≥]70 years old) or individuals with comorbidities exhibit similar safety and efficacy. This IRB approved project collected EPIC EMR data on patients that underwent MRgHIFU at Parkview Regional Medical Center from January 2023 to November 2025. 68 patients were assessed for tremor severity using Clinical Rating Scale for Tremor (CRST), quality of life using Quality of life in ET Questionnaire (QUEST), and safety profile via reported post-procedure side effects. CRST and QUEST scores improved up to 1 year from baseline in our patient cohort and efficacies in older ([≥]70 years of age) and younger (<70 years of age) patients up to 3 months post MRgHIFU were not statistically different. Effects of comorbidities on CRST or QUEST scores improvements were all transient or did not affect endpoints. Older patients showed fewer total side effects at 3 months (1.17 (95% CI: 0.47-1.87) vs 0.21 (95% CI: -0.09-0.51), p=0.017) as did patients with pulmonary disease at 1 month (1.9 (95% CI: 1.6-2.2) vs 1.1 (95% CI: 0.9-1.3), p=0.036) while patients with family history of tremor showed more side effects at day 1 (1.5 (95% CI: 0.8-2.2) vs 2.5 (95% CI: 2.1-2.9), p=0.025). Age and comorbidities were not detected to adversely affect safety or efficacy following MRgHIFU in ET patients. Further studies with larger cohorts are needed for validation of findings and assessment for equivalence.
Related
- Urinary and Sexual Function Outcomes After Ultrasound-Guided High-Intensity Focused Ultrasound for Uterine Fibroids: Associations of Lower Urinary Tract Symptoms with Fibroid Location and Uterine Morphology
- Target-dependent parameter-effect landscapes of low-intensity focused ultrasound neuromodulation in humans: a systematic review
- Low-intensity pulsed ultrasound for erectile dysfunction: a systematic review and limited quantitative synthesis
- Efficacy and Safety of 1.5‐ and 3.0‐mm High‐Intensity Focused Ultrasound for Eyebrow Lifting in Korean Adults: A Prospective Randomized Split‐Face Study
- 20-MHz high-intensity focused ultrasound for tattoo removal without pigment-specific optical targeting and with evidence for an ablation-associated transepidermal extrusion pathway
BibTeX
@misc{farmer2026high,
title = {{High Intensity Focused Ultrasound (HIFU) Thalamotomy as a Safe and Effective Treatment of Essential Tremor (ET) in Older Populations and those with Comorbidities}},
author = {A. J. Farmer and W. Young and W. Young and J. Neer and F.-L. Chang},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.14.26365548},
url = {https://www.medrxiv.org/content/10.64898/2026.10.14.26365548v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - High Intensity Focused Ultrasound (HIFU) Thalamotomy as a Safe and Effective Treatment of Essential Tremor (ET) in Older Populations and those with Comorbidities
AU - A. J. Farmer
AU - W. Young
AU - W. Young
AU - J. Neer
AU - F.-L. Chang
PY - 2026
DA - 2026/10/14
PB - medRxiv
DO - 10.64898/2026.10.14.26365548
UR - https://www.medrxiv.org/content/10.64898/2026.10.14.26365548v1
AB - Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) has been demonstrated to be a safe and effective minimally invasive therapy for essential tremor (ET). However, it is not clear whether older adults ([≥]70 years old) or individuals with comorbidities exhibit similar safety and efficacy. This IRB approved project collected EPIC EMR data on patients that underwent MRgHIFU at Parkview Regional Medical Center from January 2023 to November 2025. 68 patients were assessed for tremor severity using Clinical Rating Scale for Tremor (CRST), quality of life using Quality of life in ET Questionnaire (QUEST), and safety profile via reported post-procedure side effects. CRST and QUEST scores improved up to 1 year from baseline in our patient cohort and efficacies in older ([≥]70 years of age) and younger (<70 years of age) patients up to 3 months post MRgHIFU were not statistically different. Effects of comorbidities on CRST or QUEST scores improvements were all transient or did not affect endpoints. Older patients showed fewer total side effects at 3 months (1.17 (95% CI: 0.47-1.87) vs 0.21 (95% CI: -0.09-0.51), p=0.017) as did patients with pulmonary disease at 1 month (1.9 (95% CI: 1.6-2.2) vs 1.1 (95% CI: 0.9-1.3), p=0.036) while patients with family history of tremor showed more side effects at day 1 (1.5 (95% CI: 0.8-2.2) vs 2.5 (95% CI: 2.1-2.9), p=0.025). Age and comorbidities were not detected to adversely affect safety or efficacy following MRgHIFU in ET patients. Further studies with larger cohorts are needed for validation of findings and assessment for equivalence.
ER -